hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06330259, orgStudyIdInfo id: new AMH assay, briefTitle: Does the AMH Concentration Depend on the Menstrual Cycle?, acronym: AMH, statusModule overallStatus: COMPLETED, startDateStruct date: 2017-07-01, primaryCompletionDateStruct date: 2018-06-30, completionDateStruct date: 2019-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: University of Basel, class: OTHER, collaborators name: Roche Diagnostics, descriptionModule briefSummary: During two none subsequent natural menstrual cycles healthy female participants will be subjected every second day to blood sampling and 3D-ultrasound examinations. Together with four other key hormones the concentration of AMH (anti-Muellerian Hormone) will be measured in the serum., conditionsModule conditions: Reproductive Sterility, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ACTUAL, armsInterventionsModule interventions name: menstrual cycle monitoring, outcomesModule primaryOutcomes measure: AMH Elecsys Assay, secondaryOutcomes measure: Effect of handling of the serum on measured AMH concentrations, secondaryOutcomes measure: 3D ultrasound of both ovaries, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 39 Years, stdAges: ADULT, contactsLocationsModule locations facility: Christian De Geyter, city: Basel, zip: 4031, country: Switzerland, geoPoint lat: 47.55839, lon: 7.57327, hasResults: False
protocolSection identificationModule nctId: NCT06330233, orgStudyIdInfo id: YJiang, briefTitle: Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-04-07, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Zhejiang Chinese Medical University, class: OTHER_GOV, collaborators name: The First Affiliated Hospital of Zhejiang Chinese Medical University, descriptionModule briefSummary: This study is designed to provide the treatment plan for moxibustion for diabetic peripheral neuropathy (DPN) and provide a reference for clinical moxibustion for DPN. The patients will be randomly assigned to three clinical centers each center 44, then they will be distributed equally into 4 groups, which include the conventional treatment group and the moxibustion different minutes (5 minutes, 10 minutes, 15 minutes) per point group. The conventional treatment group will receive mecobalamin tablets and alpha-lipoic acid tablets for four weeks in conjunction with the patient's daily treatment (basal drug treatment for patients with combined hypertension and hyperlipidaemia). The frequency of moxibustion treatment is twice a week for 4 weeks. The outcomes were evaluated in the baseline period (the day before grouping), the treatment period (end of the 8th treatment) and the follow-up period (2 weeks after the end of treatment). The results of this study are expected to confirm the optimal amount of moxibustion for the treatment of diabetic peripheral neuralgia and to observe the efficacy of moxibustion in the treatment of diabetic peripheral neuralgia. It provides a reference for the clinical therapeutic operation standardization of moxibustion., conditionsModule conditions: Diabetic Peripheral Neuropathy, conditions: Pain, conditions: Moxibustion, conditions: Randomized Controlled Trial, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 132, type: ESTIMATED, armsInterventionsModule interventions name: Moxibustion, outcomesModule primaryOutcomes measure: Electrophysiological examination of the tibial nerve of the lower limb, primaryOutcomes measure: Electrophysiological examination of the peroneal nerve of the lower limb, secondaryOutcomes measure: Total clinical effectiveness, secondaryOutcomes measure: Toronto Clinical Scoring System, secondaryOutcomes measure: Visual Analogue Scale, secondaryOutcomes measure: Traditional Chinese Medicine Syndrome Score Scale, secondaryOutcomes measure: regional temperature testing, secondaryOutcomes measure: infrared thermography testing, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06330220, orgStudyIdInfo id: 2010-015-1161, briefTitle: Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-02-10, primaryCompletionDateStruct date: 2022-02-28, completionDateStruct date: 2022-02-28, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Seoul National University Hospital, class: OTHER, descriptionModule briefSummary: Although the number of wet AMD patients with the better visual acuity is increasing, the visual improvement in patients with the better vision may not be so significant after anti-vascular endothelial growth factor (VEGF) treatments because of 'ceiling effect'. The aim of current study is to investigate the improvement of visual function after aflibercept treatments using microperimetry in wet AMD patients with the better baseline visual acuity (≥20/40)., conditionsModule conditions: Age-Related Macular Degeneration, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ACTUAL, armsInterventionsModule interventions name: Aflibercept Injection [Eylea], outcomesModule primaryOutcomes measure: Retinal sensitivity change after aflibercept treatment using microperimetry in wet age-related macular degeneration patients, secondaryOutcomes measure: The correlation of OCT and OCT angiography parameters with retinal sensitivity change measured by microperimetry, eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Seoul National University Hospital, city: Seoul, zip: 03080, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06330207, orgStudyIdInfo id: IRB202301471, secondaryIdInfos id: K99DE031723, type: NIH, link: https://reporter.nih.gov/quickSearch/K99DE031723, briefTitle: An Emergency Department (ED) Provider Centered Intervention for Non-Traumatic Dental Condition Management (NTDC), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-08-01, primaryCompletionDateStruct date: 2027-02-01, completionDateStruct date: 2027-08-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: University of Florida, class: OTHER, collaborators name: National Institute of Dental and Craniofacial Research (NIDCR), descriptionModule briefSummary: The overall objective of this proposal is to understand the barriers and facilitators to non-traumatic dental condition (NTDC) management in the emergency department (ED) through quantitative and qualitative methods. The first aim will determine the national variation in NTDC prescribing in the ED and subsequent ED/urgent care revisits and hospitalizations within 30-days of an index ED visit. Using national electronic health records and integrated claims datasets and a random effects model, we will identify factors associated with prescribing for NTDC and variation at the patient, provider, hospital and state levels. The second aim identifies ED providers' perceived barriers and facilitators to the management of NTDC in the ED. Using individual in depth interviews, ED providers (physicians, advanced practice providers) will identify the facilitators and barriers to management and prescribing for NTDC in the ED., conditionsModule conditions: Emergency Department Visit, conditions: Odontalgia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Clinical decision support tool, outcomesModule primaryOutcomes measure: Acceptability and feasibility, secondaryOutcomes measure: Prescribing behavior, otherOutcomes measure: Pilot trial outcomes, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06330181, orgStudyIdInfo id: SC220178, secondaryIdInfos id: HT9425-23-1-1019, type: OTHER_GRANT, domain: Department of Depense, briefTitle: Virtual Walking Therapy for Neuropathic Pain Following Incomplete Spinal Cord Injury, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-01, completionDateStruct date: 2027-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Texas A&M University, class: OTHER, collaborators name: United States Department of Defense, collaborators name: Immersive Experience Labs, descriptionModule briefSummary: The purpose of this study is to determine if playing a virtual reality walking game can help improve neuropathic pain in adults with incomplete spinal cord injury., conditionsModule conditions: Spinal Cord Injuries, conditions: Neuropathic Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants will be randomly assigned to one of two intervention arms. Both groups receive the same number of sessions, duration of sessions, and measures procured., primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: VR Game 1, interventions name: VR Game 2, outcomesModule primaryOutcomes measure: Change in Pain Intensity, secondaryOutcomes measure: Change in Pain Quality, secondaryOutcomes measure: Change in Pain Interference, secondaryOutcomes measure: Post treatment change, secondaryOutcomes measure: Change in mood, secondaryOutcomes measure: Change in quality of life, secondaryOutcomes measure: Neurological changes, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Texas A&M University, status: RECRUITING, city: College Station, state: Texas, zip: 77843, country: United States, contacts name: Amanda Higgins, M.E.d, role: CONTACT, phone: 804-569-5965, email: sci@vrwalk.org, contacts name: Zina Trost, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.62798, lon: -96.33441, hasResults: False
protocolSection identificationModule nctId: NCT06330168, orgStudyIdInfo id: 36264PR573/2/24, briefTitle: Paravertebral Calcitonin in Thoracotomy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-28, primaryCompletionDateStruct date: 2025-04-10, completionDateStruct date: 2025-04-10, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: This prospective randomized double-blinded controlled study will be conducted to evaluate the effect of adding calcitonin to bupivacaine in thoracic paravertebral block for patients undergoing thoracotomy., conditionsModule conditions: Calcitonin, conditions: Paravertebral, conditions: Thoracotomy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, maskingDescription: triple, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: bupivacaine-calcitonin-fentanyl, interventions name: Bupivacaine-fentanyl, outcomesModule primaryOutcomes measure: morphine consumption, secondaryOutcomes measure: numerical rating scale scores, secondaryOutcomes measure: incidence of chronic pain, secondaryOutcomes measure: Side effects, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tanta University Hospitals, status: RECRUITING, city: Tanta, state: Gharbiya, zip: 31527, country: Egypt, contacts name: Osama M Rehab, MD, role: CONTACT, phone: 01095210806, email: osamarehab@med.tanta.edu.eg, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06330155, orgStudyIdInfo id: 2024-01-032, briefTitle: A Genetic Study for Alzheimer Dementia: Case-control Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: MinYoung Kim, MD, PhD, class: OTHER, descriptionModule briefSummary: The purpose of this study is to find out the difference in genetic test results between Alzheimer's dementia patients and healthy subjects.The investigators want to identify genes that are importantly related to Alzheimer's dementia., conditionsModule conditions: Alzheimer Dementia (AD), designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: genetic analysis, secondaryOutcomes measure: Measurement of Korean version of mini-mental state examination (K-MMSE), secondaryOutcomes measure: Measurement of Clinical Dementia Rating (CDR), secondaryOutcomes measure: Measurement of Geriatric Depression Scale (GDSd), eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06330129, orgStudyIdInfo id: Pegasus01_Val, briefTitle: Validity and Reliability of Trunk Strength Device, acronym: PEGASUS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Schulthess Klinik, class: OTHER, collaborators name: Balgrist Campus AG, descriptionModule briefSummary: The study aims to evaluate the accuracy and consistency of assessing trunk muscle strength using an isometric device (Pegasus, Leipzig, Germany). Thirty healthy volunteers will undergo maximal isometric strength testing with the device, repeated one week later to assess repeatability. Surface electrodes will measure muscle activation, while MRI scans will assess structural condition., conditionsModule conditions: Trunk Muscle Strength, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: CTT Pegasus, outcomesModule primaryOutcomes measure: maximal isometric trunk muscle strength, secondaryOutcomes measure: MRI muscle morphology, secondaryOutcomes measure: Electromyography (EMG) activity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 59 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06330064, orgStudyIdInfo id: DS7300-203, secondaryIdInfos id: 2023-509632-26, type: OTHER, domain: EU CTR, briefTitle: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2026-12-01, completionDateStruct date: 2028-07-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Daiichi Sankyo, class: INDUSTRY, collaborators name: Merck Sharp & Dohme LLC, descriptionModule briefSummary: This study is designed to assess the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); non-squamous non-small cell lung cancer (NSCLC); and urothelial carcinoma (UC)., conditionsModule conditions: Recurrent or Metastatic Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 260, type: ESTIMATED, armsInterventionsModule interventions name: Ifinatamab deruxtecan, outcomesModule primaryOutcomes measure: Objective Response Rate (ORR) as Assessed by Investigator, secondaryOutcomes measure: Number of Dose-limiting Toxicities in the HCC Cohort, secondaryOutcomes measure: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs), secondaryOutcomes measure: Duration of Response (DoR), secondaryOutcomes measure: Progression-free Survival (PFS), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Pharmacokinetic Parameter Maximum Concentration (CMax) for I DXd, total anti-B7-H3 antibody, and DXd, secondaryOutcomes measure: Pharmacokinetic Parameter Time to Reach Maximum Plasma Concentration (TMax) for I DXd, total anti-B7-H3 antibody, and DXd, secondaryOutcomes measure: Pharmacokinetic Parameter Half-life (t1/2) for I DXd, total anti-B7-H3 antibody, and DXd, secondaryOutcomes measure: Pharmacokinetic Parameter Minimum Concentration (Ctrough) for I DXd, total anti-B7-H3 antibody, and DXd, secondaryOutcomes measure: Pharmacokinetic Parameter Area Under the Curve (AUC) for I DXd, total anti-B7-H3 antibody, and DXd, secondaryOutcomes measure: Percentage of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline), secondaryOutcomes measure: Percentage of Participants Who Have Treatment-emergent ADA, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinical Research Alliance, Inc., status: RECRUITING, city: Westbury, state: New York, zip: 11590, country: United States, geoPoint lat: 40.75566, lon: -73.58763, hasResults: False
protocolSection identificationModule nctId: NCT06330051, orgStudyIdInfo id: KY 2023-184-02, briefTitle: The Improve Acute Reperfusion Treatment Quality for Ischemic Stroke Through Spatiotemporal Computing in China, acronym: IMPROVE-II, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2025-03-18, completionDateStruct date: 2025-04-20, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Beijing Tiantan Hospital, class: OTHER, descriptionModule briefSummary: This study intends to construct the goal-oriented integrated intervention model for AIS in-hospital procedure through the spatiotemporal positioning and the P-D-C-A cycle for continuous improvement (FAST model). Then a multicenter, evaluator-blind, cluster-randomized controlled study aims to verify the validity and safety of this FAST model., conditionsModule conditions: Acute Ischemic Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: SINGLE, maskingDescription: After 2 months of baseline information collection,10 hospitals will be seleted and then randomly assigned to the control and intervention groups according to hospital level and baseline DNT to reduce the imbalance between the two groups. We will not indicate to any hospital the grouping type of other hospitals. If the selected hospital is unable to complete the study for some reason during the operation, the hospital with conditions to carry out the replacement will be selected from the hospitals of the same region, the same level and the same scale., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: improvement acute reperfusion treatment quality for stroke through spatiotemporal computing, outcomesModule primaryOutcomes measure: The Door to Needle time (DNT) for intravenous thrombolytic therapy in eligible patients within 4.5 hours of onset., secondaryOutcomes measure: The Door to Puncture time (DPT) for endovascular treatment within 6 hours of onset in eligible patients admitted to hospital within 4.5 hours of onset., secondaryOutcomes measure: The rate of intravenous thrombolytic therapy in eligible patients within 4.5 hours of onset., secondaryOutcomes measure: The rate of endovascular treatment within 6 hours of onset in eligible patients admitted to hospital within 4.5 hours of onset., secondaryOutcomes measure: Incidence of symptomatic intracranial hemorrhage (sICH) within 36 hours of receiving reperfusion therapy., secondaryOutcomes measure: Proportion of patients with 90-day favorable functional outcome., secondaryOutcomes measure: Proportion of patients with 90-day independent functional outcome., secondaryOutcomes measure: in-hospital mortality, secondaryOutcomes measure: 90-day mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False